VEGFA and wet macular degeneration: Pegaptanib (MacugenTM, Eyetech, Inc.)is an aptamer that selectively binds to and neutralizes VEGF-A165, but not VEGF-A121, and was the first anti-VEGF therapy approved for the treatment of wet AMD [23, 24].